AbbVie Reaches Deal With Pfizer To Delay Seventh Humira Biosimilar

AbbVie announced Friday (Nov. 30) that it has reached an agreement to delay the launch of Pfizer’s biosimilar referencing the blockbuster arthritis drug Humira. The latest settlement is AbbVie’s seventh with different companies to delay biosimilars of Humira, which is the best-selling prescription drug in the world. Pfizer will be allowed to launch on Nov. 20, 2023 if it obtains FDA approval. Amgen can release its biosimilar in January of that same year, Samsung Bioepis in June 2023, Mylan in...